Literature DB >> 1285737

Prediction of mortality in patients with cystic fibrosis.

E Kerem1, J Reisman, M Corey, G J Canny, H Levison.   

Abstract

BACKGROUND: The majority of patients with cystic fibrosis die in early adulthood of lung disease. Lung transplantation is a treatment option for patients with advanced pulmonary disease, although the waiting period for organs may be as long as two years. Our purpose was to determine whether the risk of death due to respiratory failure could be predicted one or two years in advance on the basis of pulmonary function, blood gas levels, and nutritional status.
METHODS: The study cohort consisted of 673 patients followed between 1977 and 1989. In each patient, pulmonary function, blood gas levels, nutritional status, and vital status were assessed between 1977 and 1987. Cox proportional-hazards regression analysis was used to compute the relative risk of death within one or two years after particular measurements. The effects of age and sex on mortality were also included in the analysis.
RESULTS: One hundred ninety patients (28 percent) died during the study period. Overall, patients with a forced expiratory volume in one second (FEV1) less than 30 percent of the predicted value, a partial pressure of arterial oxygen below 55 mm Hg, or a partial pressure of arterial carbon dioxide above 50 mm Hg had two-year mortality rates above 50 percent. Among the laboratory measurements, the FEV1 was the most significant predictor of mortality, but age and sex were also significant in predicting risk. After adjustment for age and sex, the relative risk of death within two years was 2.0 (95 percent confidence interval, 1.9 to 2.2) for each decrement in the FEV1 of 10 percent below the predicted value. Among patients with the same FEV1, the relative risk of death was 2.0 (95 percent confidence interval, 1.5 to 2.6) in patients 10 years younger than other patients, and 2.2 (1.6 to 3.1) in female patients as compared with male patients.
CONCLUSIONS: Patients with cystic fibrosis should be considered candidates for lung transplantation when the FEV1 falls below 30 percent of the predicted value. Female patients and younger patients may need to be considered for transplantation at an earlier stage.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1285737     DOI: 10.1056/NEJM199204303261804

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  181 in total

Review 1.  Current status of paediatric heart, lung, and heart-lung transplantation.

Authors:  M Burch; P Aurora
Journal:  Arch Dis Child       Date:  2004-04       Impact factor: 3.791

2.  Highlights of the North American Cystic Fibrosis Conference 2009.

Authors:  Andrew M Jones; Jennifer Helm; Ruth Richmond; Emily Mason-Smith; Amanda Brennan
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

3.  Quantile regression for doubly censored data.

Authors:  Shuang Ji; Limin Peng; Yu Cheng; HuiChuan Lai
Journal:  Biometrics       Date:  2011-09-27       Impact factor: 2.571

4.  Macrophage migration inhibitory factor enzymatic activity, lung inflammation, and cystic fibrosis.

Authors:  Huzaifa Adamali; Michelle E Armstrong; Anne Marie McLaughlin; Gordon Cooke; Edward McKone; Christine M Costello; Charles G Gallagher; Lin Leng; John A Baugh; Günter Fingerle-Rowson; Richard J Bucala; Paul McLoughlin; Seamas C Donnelly
Journal:  Am J Respir Crit Care Med       Date:  2012-05-16       Impact factor: 21.405

5.  Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung.

Authors:  G B Pier; M Grout; T S Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

6.  Invasive Pulmonary Fungal Infections in Cystic Fibrosis.

Authors:  Carsten Schwarz; Claudia Brandt; Paul Whitaker; Sivagurunathan Sutharsan; Heino Skopnik; Silvia Gartner; Christina Smazny; Jobst F Röhmel
Journal:  Mycopathologia       Date:  2017-09-01       Impact factor: 2.574

7.  In statistics we trust: Towards the careful derivation and interpretation of meaningful survival estimates in cystic fibrosis.

Authors:  N Mayer-Hamblett; D Polineni; S L Heltshe
Journal:  J Cyst Fibros       Date:  2018-02-01       Impact factor: 5.482

8.  Resource Use Evaluation of Tobramycin Formulations in a State Medicaid Program.

Authors:  Shellie L Keast
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

Review 9.  The Evolution of Cystic Fibrosis Care.

Authors:  Jessica E Pittman; Thomas W Ferkol
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

10.  Lung transplantation for cystic fibrosis.

Authors:  Frederick R Adler; Paul Aurora; David H Barker; Mark L Barr; Laura S Blackwell; Otto H Bosma; Samuel Brown; D R Cox; Judy L Jensen; Geoffrey Kurland; George D Nossent; Alexandra L Quittner; Walter M Robinson; Sandy L Romero; Helen Spencer; Stuart C Sweet; Wim van der Bij; J Vermeulen; Erik A M Verschuuren; Elianne J L E Vrijlandt; William Walsh; Marlyn S Woo; Theodore G Liou
Journal:  Proc Am Thorac Soc       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.